119th Congress · introduced in the Senate · Mar 11, 2025
Tariff Transparency Act of 2025
Official title from Congress.gov
Latest action (Mar 11, 2025): Read twice and referred to the Committee on Finance.
View on Congress.govPolicy area: Foreign Trade and International Finance
Congressional Research Service summary, version: Introduced in Senate (Mar 11, 2025)
Tariff Transparency Act of 2025
This bill requires the U.S. International Trade Commission to investigate and report to Congress on the impact of additional tariffs on imports from Canada and Mexico. (President Donald J. Trump issued executive orders on February 1, 2025, to impose an additional 25% tariff on most imports from Canada and Mexico. These tariffs applied to all imports, except for Canadian energy or energy resources, which have an additional 10% tariff.)
Specifically, the report must assess (1) the impact of these tariffs on consumer prices; (2) the impact of any retaliation (e.g., retaliatory tariffs and export restrictions) imposed by Canada and Mexico on U.S. consumers, small businesses, farmers, and ranchers; and (3) the impact of the threat of tariffs and associated uncertainty with respect to the trade relationship between the United States, Canada, and Mexico on U.S. businesses.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
4 citations.
TEVA PHARMACEUTICALS USA INC · lobbying firm or registrant: TEVA PHARMACEUTICALS USA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Tariff (miscellaneous tariff bills)
$310,000
Spent on own lobbying
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TEVA PHARMACEUTICALS USA INC · lobbying firm or registrant: TEVA PHARMACEUTICALS USA, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 17, 2026 · issue area: Tariff (miscellaneous tariff bills)
$380,000
Spent on own lobbying
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TEVA PHARMACEUTICALS USA INC · lobbying firm or registrant: TEVA PHARMACEUTICALS USA, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Tariff (miscellaneous tariff bills)
$1,100,000
Spent on own lobbying
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
TEVA PHARMACEUTICALS USA INC · lobbying firm or registrant: TEVA PHARMACEUTICALS USA, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 14, 2026 · issue area: Tariff (miscellaneous tariff bills)
$360,000
Spent on own lobbying
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing